ALVONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ALVOW
Alvotech
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$5.03+0.03 (+0.60%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 50.3
- Dividend yield
- –
Alvotech statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Alvotech | Industry median |
|---|---|---|
| Market Cap | $1.57B | $166.30M |
| Enterprise Value | $2.73B | $88.19M |
| PE Ratio | 50.30 | 20.44 |
| PS Ratio | 2.68 | 3.65 |
Enterprise value
| Measure | Alvotech | Industry median |
|---|---|---|
| EV / Sales | 4.66 | 2.51 |
| EV / EBITDA | 23.55 | 14.65 |
| EV / EBIT | 34.94 | 19.00 |
Income (trailing twelve months)
| Measure | Alvotech | Industry median |
|---|---|---|
| Revenue | $586.32M | $58.34M |
| Gross Profit | $350.76M | $105.94M |
| Operating Income | $78.21M | -$21.40M |
| Pretax Income | $136.35M | -$14.34M |
| EBITDA | $116.06M | -$16.91M |
| EPS (Diluted) | $0.10 | -$0.83 |
Margins
| Measure | Alvotech | Industry median |
|---|---|---|
| Gross Margin | 59.8% | 52.9% |
| Operating Margin | 13.3% | -44.0% |
| Pretax Margin | 23.3% | -13.3% |
| EBITDA Margin | 19.8% | -30.2% |
| FCF Margin | -19.6% | -9.27% |
Returns
| Measure | Alvotech | Industry median |
|---|---|---|
| Return on Capital Employed (ROCE) | 6.23% | -38.1% |
Growth
| Measure | Alvotech | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 19.7% | 5.96% |
| Revenue Growth (3Y CAGR) | 91.9% | 2.25% |
| Revenue Growth (5Y CAGR) | 54.5% | 6.48% |
Balance sheet
| Measure | Alvotech | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $142.75M | $61.43M |
| Total Debt | $1.31B | $118.52M |
| Net Cash (Debt) | -$1.16B | $15.35M |
| Net Cash Per Share | -$3.73 | $0.66 |
| Working Capital | $213.79M | $76.81M |
Financial position
| Measure | Alvotech | Industry median |
|---|---|---|
| Current Ratio | 1.65 | 3.34 |
| Quick Ratio | 0.57 | 2.44 |
| Debt / EBITDA | 11.25 | 3.44 |
| Net Debt / EBITDA | 10.02 | 2.36 |
| Interest Coverage | 0.52 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Alvotech | Industry median |
|---|---|---|
| Operating Cash Flow | -$50.20M | -$12.35M |
| Capital Expenditures | -$64.47M | -$1.08M |
| Free Cash Flow | -$114.67M | -$20.22M |
| FCF Per Share | -$0.37 | -$0.42 |
Efficiency
| Measure | Alvotech | Industry median |
|---|---|---|
| Asset Turnover | 0.39 | 0.39 |
| Inventory Turnover | 1.23 | 2.70 |
| Revenue Per Employee | $586.32K | $404.87K |
| Employee Count | 1,000 | 74 |
Dividends and yields
| Measure | Alvotech | Industry median |
|---|---|---|
| FCF Yield | -7.31% | -8.72% |
Shares
| Measure | Alvotech | Industry median |
|---|---|---|
| Shares Outstanding | 312,021,000 | 58,127,000 |
| Shares Change (YoY) | 8.74% | 10.9% |
| Float | 100,721,000 | 49,136,700 |
| Shares Held by Insiders | 67.7% | 11.6% |
Taxes
| Measure | Alvotech | Industry median |
|---|---|---|
| Income Tax | $108.43M | $79.87K |
| Effective Tax Rate | 79.5% | 20.6% |
Scores
| Measure | Alvotech | Industry median |
|---|---|---|
| Altman Z-Score | -0.96 | -0.22 |
Calculated by StockData from Alvotech's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.